Department of Internal Medicine, University of Pavia, Via Golgi 19, Pavia, 27100, Italy
Molecular Cardiology, IRCCS Istituti Clinici Scientifici Maugeri, Via Maugeri 10, Pavia, 27100, Italy
Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA
Department of Internal Medicine, University of Pavia, Via Golgi 19, Pavia, 27100, Italy
Molecular Cardiology, IRCCS Istituti Clinici Scientifici Maugeri, Via Maugeri 10, Pavia, 27100, Italy
Molecular Cardiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), C/ Melchor Fernandez Almagro 3, Madrid, 28029, Spain
Corresponding author. Tel: +390382592040, Fax: +390382592059, E-mail: [email protected]
Conflict of interest: S.G.P. holds intellectual property but not the ownership of patents on gene therapy for CPVT via AAV-mediated CASQ2 overexpression (WO2019193563; US20130059905). S.G.P. and R.B. hold intellectual property but not the ownership of a patent on gene therapy for CPVT by allele specific silecing of RyR2 (WO2017141157). S.G.P. is member of the advisory board of Solid Biosciences. The other authors declare no conflict of interest.
Received April 18, 2024
Received in revised form July 22, 2024
Accepted July 30, 2024
Revised October 01, 2024
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
